Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week (JACC October 2019-1)

Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week (JACC October 2019-1)  is organized by American College of Cardiology (ACC).

Release Date: Sep 23, 2019
?Expired Date: Sep 22, 2020

Target Audience:
JACC Journal CME/MOC/ECME is intended for physicians who treat patients with cardiovascular disease.

Credit Offered:
• 1 CME Credit
• 1 ECME Credit
• 1 MOC Credit

Description:
In this review, we have summarized the most updated evidence on epidemiology, pathophysiologic mechanisms, and management strategies of various CVAEs associated with ICIs. We have also incorporated the highlights from recent guidelines published by the National Comprehensive Cancer Network on ICI-related cardiovascular toxicities.

Learning Objectives:
After reading this article the reader should be able to:
• Discuss the principles of therapy with immune checkpoint inhibition in patients with cancer.
• Explain common cardiovascular adverse events associated with the use of immune checkpoint inhibitors.
• Diagnose a case of checkpoint inhibition–induced myocarditis.

Additional details will be posted as soon as information is available.